In Vivo Confocal Microscopy Tumor Atlas Study
1 other identifier
interventional
150
1 country
1
Brief Summary
This study aims to create an atlas based on the preliminary experience of the first feasibility study in neurosurgery. Hypothesis: That a confocal endomicroscope can be used during neurosurgery to provide in vivo histology that enables documentation of neurological pathology across a range of tumor ypes and grades, suitable for comparison with traditional histopathology from site-matched biopsies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_1
Started Nov 2009
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2009
CompletedFirst Submitted
Initial submission to the registry
November 10, 2009
CompletedFirst Posted
Study publicly available on registry
November 11, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2010
CompletedNovember 11, 2009
November 1, 2009
1.1 years
November 10, 2009
November 10, 2009
Conditions
Outcome Measures
Primary Outcomes (1)
Generation of an atlas documenting the comparative features of in vivo microscopy versus traditional histopathology of site-matched biopsies across a range of tumor types and grades.
During surgery
Secondary Outcomes (2)
Test the ability of an expert neuropathologist to predict the outcome of biopsies based on the confocal images collected in vivo.
One week
Capture usability and workflow aspects for the confocal device.
During surgery
Study Arms (1)
All patients
EXPERIMENTALInterventions
Endomicroscopic images and biopsies are taken at several positions on the tumor.
Eligibility Criteria
You may qualify if:
- All patients with neurological pathology requiring surgery in which tumour resection might be evaluated by using biopsy
You may not qualify if:
- History of allergy to fluorescein
- Patients on beta-blockers or ACE inhibitors
- Pregnant women
- Inability to give informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Barrow Neurological Institute, St. Joseph's Hospital and Medical Center
Phoenix, Arizona, 85013, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Peter Nakaji, MD
Barrow Neurological Institute, St. Joseph's Hospital and Medical Center
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
November 10, 2009
First Posted
November 11, 2009
Study Start
November 1, 2009
Primary Completion
December 1, 2010
Study Completion
December 1, 2010
Last Updated
November 11, 2009
Record last verified: 2009-11